

United States Patent and Trademark Office

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE

Washington, D.C. 2023: www.uspto.gov

APPLICATION NUMBER

FILING RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/780,576

SAN DIEGO, CA 92122

02:09:2001

Olivier Civelli

P-UC 4530

23601 CAMPBELL & FLORES LLP 4370 LA JOLLA VILLAGE DRIVE 7TH FLOOR



CONFIRMATION NO. 1610
FORMALITIES LETTER
OC0000000006486828

Date Mailed: 08/28/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For guestions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

PATENT

Our Docket: P-UC 4530

2005 B T MAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In xe Application of)
Civelli et al.) Examiner: Unknown
Serial No.: 09/780,576) Group Art Unit: Unknown
Filed: February 9, 2001	 I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in
For: ADP-GLUCOSE RECEPTOR	an envelope addressed to: Box Sequence, Commissioner for Patents, Washington, D.C. 20231, on October 26, 2001.
	ByMelanie K. Webster, Reg. No. 45,201
BOX SEQUENCE	Molanie IX. Prositel, 116g. 116. 10,20
Commissioner for Patents Washington, D.C. 20231	October 26, 2001 Date of Signature

Sir:

TRANSMITTAL

Responsive to the NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES mailed August 28, 2001, the following are provided:

- \underline{x} (1) a copy of the NOTICE;
- x (2) a copy of the sequence listing in computer
 readable form;
- (3) a Preliminary Amendment;
- \underline{x} (4) paper copy of sequence listing, pages 1 through 5;
- \underline{x} (5) a statement under 37 CFR §1.821(f) and (g);

Please charge any additional fees or credit any overpayment to Deposit Account No. 03-0370. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: October 26, 2001

Melanie K. Webster Registration No. 45,201 Telephone: (858) 535-9001

Telephone: (858) 535-9001 Facsimile: (858) 535-8949

CAMPBELL & FLORES LLP 4370 La Jolla Village Drive, 7th Floor San Diego, California 92122 USPTO CUSTOMER NO. 23601



PATENT

Our Docket: P-UC 4530

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Civelli et al.

Serial No.: 09/780,576

Filed: February 9, 2001

For: ADP-GLUCOSE RECEPTOR

Commissioner for Patents Washington, D.C. 20231

Sir:

Examiner: Unknown

Group Art Unit: Unknown

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on October 26, 2001.

By Melanie K. Webster, Reg. No. 45,201

October 26, 2001

Date of Signature

STATEMENT UNDER 37 C.F.R. § 1.821(f) and (q)

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821(g) herein does not include new matter.

Respectfully submitted,

October 26, 2001

Date

Melanie K. Webster

Facsimile:

Registration No. 45,201 Telephone: (858) 535-9001

(858) 535-8949

CAMPBELL & FLORES LLP 4370 La Jolla Village Drive 7th Floor San Diego, California 92122 USPTO CUSTOMER NO. 23601 SIDS BO MAL

Computer-Readable Copy of Sequence
Listing Pages 1 through 5, and
Paper Copy of Sequence Listing
Pages 1 through 5
Attorney Docket No.: P-UC 4530
Serial No.? Q9/780,576

IAN 0 9 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on October 26, 2001.

By Melanie K. Webster, Reg. No. 45,201

October 26, 2001

Date of Signature